Update shared on 07 Nov 2025
Narrative Update on Ryman Healthcare Analyst Price Target
Analysts have maintained their price target for Ryman Healthcare at $3.07, with only minor adjustments to underlying assumptions. They cite stable forecasts for revenue growth and profit margins as reasons for the consistent valuation.
Valuation Changes
- Fair Value estimate remains unchanged at NZ$3.07 per share.
- Discount Rate has risen slightly from 6.98% to 7.10%.
- Revenue Growth forecast holds steady at approximately 7.42%.
- Net Profit Margin is unchanged at 42.31%.
- Future P/E ratio has increased marginally from 11.72x to 11.75x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.